Molecules/MIRVETUXIMAB SORAVTANSINE

MIRVETUXIMAB SORAVTANSINE

Molecular Identity

Antibody drug conjugateApprovedFirst approved 2022

Mechanism of action: Folate receptor alpha binding agent

Molecular Formula

0.00

Molecular Weight

g/mol

ElahereELAHEREIMGN-853IMGN853MIRVETUXIMAB SORAVTANSINAMIRVETUXIMAB SORAVTANSINEMIRVETUXIMAB SORAVTANSINE GYNXMIRVETUXIMAB SORAVTANSINE-GYNX

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Trials and conditions connected to MIRVETUXIMAB SORAVTANSINE

Loading drug network...